Updates to the Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection were released on Thursday, November 1, 2012. Please send your comments to ContactUs@aidsinfo.nih.gov by November 15, 2012.
Corrections were made to the guideline. For a description of the changes, please see the correction notice.
(Last updated:11/1/2012; last reviewed:11/1/2012)
Adolescent (>18 years)/adult dose (antiretroviral [ARV]-naive patients only):
Resistance: The International Antiviral Society-USA (IAS-USA) maintains a list of updated resistance mutations (see http://www.iasusa.org/resistance_mutations/index.html).
Pediatric Use: The pharmacokinetics, safety, and efficacy of rilpivirine in pediatric patients have not been established. An international trial currently under way is investigating a 25-mg dose of rilpivirine in combination with two nucleoside reverse transcriptase inhibitors in antiretroviral-naive children aged 12 to 18 years who weigh at least 40 kg.